EDAP TMS SA reported third-quarter 2026 total revenues of $9.8 million, a 26% increase from the prior year period, driven by seven Focal One system sales and a 32% rise in U.S. procedure volume. Gross margin expanded to 51.4% from 46.6%, while operating loss widened to $7.8 million due to higher compensation and marketing expenses. Net loss narrowed to $4.5 million, or ($0.10) per share, compared to a net loss of $5.9 million in the prior year, aided by a $2.6 million non-cash gain on warrant fair value adjustments. The company narrowed its full-year 2026 revenue guidance to $50.0–$52.0 million from the previous range of $50.0–$54.0 million. EDAP TMS develops, manufactures, and markets minimally invasive medical devices worldwide using proprietary focused ultrasound technology.
